Logo

DXR

Daxor Corporation

DXR

Daxor Corporation • NASDAQ
$13.30 ▲ 0.00% (+0.00)
Market Cap $66.29 M
52w High $14.15
52w Low $6.55
Dividend Yield 0%
P/E 83.13
Volume 158
Outstanding Shares 4.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $18.348K ▼ $287.847K ▼ $-369.701K ▼ -2.015K% ▼ $-0.074 ▼ $0 ▼
Q4-2024 $695.307K ▲ $1.225M ▲ $2.167M ▲ 311.683% ▲ $0.44 ▲ $3.341M ▲
Q2-2024 $71.756K ▼ $369.306K ▼ $-1.631M ▼ -2.273K% ▼ $-0.34 ▼ $-1.283M ▼
Q4-2023 $82.448K ▲ $503.016K ▼ $3.318M ▲ 4.024K% ▲ $0.72 ▲ $0
Q2-2023 $80.974K $3.074M $-3.037M -3.751K% $-0.32 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $0 $35.9M ▼ $272.427K ▼ $35.628M ▼
Q4-2024 $0 $36.633M ▲ $840.296K ▼ $35.792M ▲
Q2-2024 $0 $34.376M ▼ $1.72M ▲ $32.655M ▼
Q4-2023 $0 $34.869M ▲ $858.758K ▲ $34.01M ▲
Q2-2023 $0 $30.359M $0 $30.359M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-369.701K ▼ $467.039K ▲ $773.993K ▼ $-467.039K ▲ $0 $467.039K ▲
Q4-2024 $2.167M ▲ $-502.047K ▲ $1.422M ▲ $-919.675K ▼ $0 ▼ $-502.05K ▲
Q2-2024 $-1.631M ▼ $-1.413M ▲ $1.038M ▼ $893.984K ▲ $518.773K ▲ $-893.99K ▲
Q4-2023 $3.318M ▲ $-3.79M ▼ $3.046M ▲ $783.128K ▼ $40K ▲ $-3.79M ▼
Q2-2023 $-3.037M $-2.612M $-300.301K $2.872M $-40K $-2.612M

Five-Year Company Overview

Income Statement

Income Statement Daxor looks more like a development-stage medical technology company than a mature equipment maker. Reported revenue is extremely small and inconsistent, which suggests commercialization is still early and the installed base of its analyzers is limited. Profitability has bounced around, with per‑share earnings swinging from losses to unusually high gains, which often reflects one‑time items, grants, or accounting effects rather than stable, repeatable profits. Overall, the income statement points to a company still in the build‑out and validation phase of its business model, not yet in a steady, scaled revenue phase. The sparse data also means year‑to‑year trends should be viewed with caution.

Balance Sheet

Balance Sheet The balance sheet appears very small in absolute size, with modest assets and equity and essentially no reported debt. That combination points to a lean capital structure and limited financial leverage, which can reduce financial risk but also highlights that this is a micro‑scale business. The lack of reported cash detail makes it hard to judge the true liquidity cushion or runway. In simple terms, Daxor looks conservatively financed but resource‑constrained, so its ability to grow will depend heavily on external funding, grants, or future commercial traction.

Cash Flow

Cash Flow The cash flow line items are essentially blank, which likely reflects limited operating scale and/or incomplete disclosure in the data provided. Without clear operating or free cash flow figures, it is hard to assess how much cash the business generates or burns in a typical year. For a company with such a small financial footprint and an innovation‑heavy model, it is reasonable to assume that internal cash generation is still weak and that investment in development and commercialization is not yet self‑funded. This uncertainty around cash dynamics is an important risk dimension to keep in mind.

Competitive Edge

Competitive Edge Daxor’s competitive position is built around a very narrow but deep niche: precise blood volume measurement. It has an FDA‑cleared system that is described as the only test of its kind, backed by decades of clinical work and many studies, which together create both scientific credibility and meaningful regulatory barriers for would‑be competitors. Exclusive control over its tracer supply, a long operating history in this specialty, and strong intellectual property further strengthen its moat. The flip side is that the niche is highly specialized and physician adoption takes time, so real‑world market share and revenue scale may lag behind the clinical promise for quite a while.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Daxor’s strategy. The company has built a flagship blood volume analyzer and is now working on faster, more portable versions, lab‑based services, and new tracers that could simplify handling and broaden use. It is also pursuing decision‑support tools for conditions like sepsis, exploring military and emergency applications, and expanding into related diagnostics via additional agents such as GFR testing. Collaboration with large institutions and government agencies, plus ongoing clinical trials, suggest an active and forward‑leaning R&D program. The main question is not innovation quality, but how quickly these efforts can translate into broad adoption and sustainable commercial returns.

Summary

Overall, Daxor looks like a highly specialized, innovation‑driven healthcare technology company operating at a very small financial scale. Its strength lies in a differentiated diagnostic platform with deep clinical and regulatory foundations, meaningful intellectual property, and a focused push into next‑generation devices and new use cases. At the same time, reported revenue is minimal, profitability is uneven and likely influenced by non‑recurring factors, and cash‑flow information is sparse, all of which point to early‑stage commercialization risk. The story is one of strong technical and clinical positioning in a narrow field, but with significant uncertainty around how quickly and reliably that can be converted into steady, sizable business performance.

NEWS

November 25, 2025 · 8:00 AM UTC

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Read more

October 21, 2025 · 8:00 AM UTC

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Read more

September 30, 2025 · 8:00 AM UTC

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Read more

September 23, 2025 · 8:00 AM UTC

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Read more

September 4, 2025 · 8:00 AM UTC

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Read more